Bone Biologics Co. (OTC:BBLG – Get Free Report)’s share price was down 1.9% on Tuesday . The stock traded as low as $1.01 and last traded at $1.02. Approximately 44,014 shares changed hands during mid-day trading, a decline of 80% from the average daily volume of 216,571 shares. The stock had previously closed at $1.04.
Bone Biologics Price Performance
The firm has a market capitalization of $2.54 million, a price-to-earnings ratio of -0.02 and a beta of 0.55. The stock has a fifty day moving average of $1.04 and a two-hundred day moving average of $1.37.
About Bone Biologics
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.
Recommended Stories
- Five stocks we like better than Bone Biologics
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Hims & Hers Earnings Could Be a Game Changer—What to Do Now
- Using the MarketBeat Dividend Yield Calculator
- DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI Stocks
- How to Most Effectively Use the MarketBeat Earnings Screener
- Mortgage Market Bottom? Why Rocket Companies Could Be a Buy
Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
